Research results on Eisai's dementia drug lecanemab being highly effective with continuous use

July 31, 2024 9:22 AM GMT+9

Research results showing that the effects of the Alzheimer's disease treatment drug “lecanemab,” which were jointly developed by Eisai and US Biogen, increased with continuous use on early-stage patients, and that there were no new safety issues were presented at the Alzheimer's Association's international conference held in Philadelphia, USA on the 30th.
When effects were investigated on approximately 95% of clinical investigators who continued treatment, the decline in cognitive function was suppressed by 31% compared to patients who did not receive treatment after 3 years.
Also, no new safety issues have been identified during the past 3 years. According to Christopher Van Dyke of the Yale University Alzheimer's Disease Research Team, symptoms such as brain swelling and bleeding associated with lecanemab mainly occurred within 6 months of starting treatment. Recanemab has the function of removing amyloid from the brain.

Lin Kramer, Eisai's chief clinical officer, stated in an interview with Reuters that “it is definitely more effective in the long term than in the short term.”